Currently, there are 41.52M common shares owned by the public and among those 39.73M shares have been available to trade.
The company’s stock has a 5-day price change of -6.97% and -29.56% over the past three months. KNSA shares are trading -6.27% year to date (YTD), with the 12-month market performance down to -1.75% lower. It has a 12-month low price of $16.56 and touched a high of $28.15 over the same period. KNSA has an average intraday trading volume of 359.12K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.79%, -11.05%, and -15.23% respectively.
Institutional ownership of Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) shares accounts for 55.77% of the company’s 41.52M shares outstanding.
It has a market capitalization of $1.34B and a beta (3y monthly) value of 0.32. The earnings-per-share (ttm) stands at -$0.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.25% over the week and 3.31% over the month.
Earnings per share for the fiscal year are expected to decrease by -292.65%, and 246.20% over the next financial year.
Looking at the support for the KNSA, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on September 13, 2024, with the firm’s price target at $40. Wells Fargo coverage for the Kiniksa Pharmaceuticals International Plc (KNSA) stock in a research note released on May 03, 2024 offered a Overweight rating with a price target of $34. BofA Securities was of a view on June 29, 2020 that the stock is Buy, while BofA/Merrill gave the stock Buy rating on April 01, 2020, issuing a price target of $25. Barclays on their part issued Overweight rating on March 11, 2019.
